Blog
RSS FeedPosted by Michael Wonder on 16 Apr 2026
‘Trojan horse’ treatment recommended for people with multiple myeloma
16 April 2026 - Around 1,600 people a year in England with multiple myeloma are set to benefit from a ...
Posted by Michael Wonder on 16 Apr 2026
Health Canada approves Cysklar (cysteamine ophthalmic solution) 0.44% for treatment of corneal crystals in people with cystinosis
15 April 2026 - Leadiant Biosciences today announced that Health Canada has approved Cysklar (cysteamine ophthalmic solution) 0.44%, a topical eye ...
Posted by Michael Wonder on 16 Apr 2026
Health Canada approves neffy - the first needle free epinephrine spray for anaphylaxis
15 April 2026 - ALK-Abello today announced that Health Canada has approved neffy 2 mg for the emergency treatment of ...
Posted by Michael Wonder on 14 Apr 2026
Travere Therapeutics announces full FDA approval of Filspari (sparsentan), the first and only approved medicine for FSGS
13 April 2026 - Travere Therapeutics today announced that the US FDA has approved Filspari (sparsentan) to reduce proteinuria in adult ...
Posted by Michael Wonder on 14 Apr 2026
Saphnelo subcutaneous approved in Canada for the treatment of systemic lupus erythematosus
13 April 2026 - Health Canada has granted a notice of compliance for Saphnelo (anifrolumab injection) for subcutaneous self-administration via a ...
Posted by Michael Wonder on 13 Apr 2026
Dupixent (dupilumab) approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
13 April 2026 - Regeneron Pharmaceuticals and Sanofi today announced that the European Commission has approved Dupixent (dupilumab) for the treatment ...
Posted by Michael Wonder on 11 Apr 2026
MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronaemia syndrome
10 April 2026 - The MHRA has today approved olezarsen (Tryngolza) to help treat adults with familial chylomicronaemia syndrome. ...
Posted by Michael Wonder on 11 Apr 2026
FDA approves updated Vabysmo label to extend treatment for macular oedema following retinal vein occlusion beyond six months
9 April 2026 - Genentech has received US FDA approval of Vabysmo (faricimab-svoa) for the treatment of macular oedema due to ...
Posted by Michael Wonder on 10 Apr 2026
Cemiplimab in cutaneous squamous cell carcinoma: no suitable data due to insufficient observation period
16 March 2026 - To rule out a recurrence, patients must be monitored for a sufficient period of time, even after ...
Posted by Michael Wonder on 10 Apr 2026
Wegovy injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
9 April 2026 - – The EMA has approved an update to the product information for Wegovy injection that allows ...
Posted by Michael Wonder on 10 Apr 2026
Replimune receives complete response letter from the FDA for RP1 biologics license application for the treatment of advanced melanoma
10 April 2026 - Replimune Group today announced that the company received a complete response letter from the US FDA ...
Posted by Michael Wonder on 10 Apr 2026
Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the US
9 April 2026 - Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day ...
Posted by Michael Wonder on 10 Apr 2026
Sanofi becomes market authorisation holder for Nuvaxovid in Canada, expanding COVID-19 vaccine choices for Canadians
9 April 2026 - Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 ...
Posted by Michael Wonder on 10 Apr 2026
Sobi receives Health Canada approval for Empaveli (pegcetacoplan) for the treatment of C3G and primary IC-MPGN
9 April 2026 - Approval supported by Phase 3 52 week VALIANT study demonstrated reduced proteinuria, stabilsed kidney function and ...
Posted by Michael Wonder on 08 Apr 2026
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps
8 April 2026 - GSK today announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as an add-on ...